Name of Patient: _____________________________

Diagnosis: __________________________________
Physician: __________________________________
Drug Data
Generic Name
Oral Poliovirus
Vaccine
Trade Name

Classification
Therapeutic Class

Mechanism of
Action
Chemical
stimulates the immune system
to produce anti-poliovirus
antibodies against Sabin
poliovirus types 1, 2, and 3.
The live virus persists in the
gastrointestinal tract for 4-6
weeks, inducing both mucosal
and serum anti-poliovirus
antibodies capable of
opsonization, neutralization,
and complement activation.

Pts Dose

Minimum Dose
0.5 ml

Age: _____
Sex: _____
Date of Admission: _______________

Pharmacokinetics

Pharmacologic
Class

Indications

Contraindications
Contraindications

Side Effects

Intended for polio

prophylaxis in infants 612 weeks of age, all
unimmunized children up
to 18 years of age, and
high-risk adults.
OPV is highly effective in
preventing natural
poliovirus-induced
neurologic sequelae.

The poliovirus vaccine should

be used with caution in
patients with a history of
neomycin hypersensitivity or
streptomycin hypersensitivity
because these agents may be
used in the preparation of
OPV. A history of delayedtype allergic reactions is not
an absolute contraindication
to OPV administration.

Administration of OPV is
associated with a low
incidence of paralytic
poliomyelitis in vaccines.
The risk of developing
paralytic poliomyelitis has
also been associated with
intramuscular injections
of medications received
30 days prior to the onset
of paralysis.

Poliovirus antibodies are

distributed into breast
milk.

Precautions

Maximum Dose
0.5 ml

Onset
7-10 days

Contents

Peak
3 weeks

Duration

Drug Interaction

Drug Half-Life

Concomitant administration
of immunosuppressives can
decrease the immunological
response to OPV and
potentiate viral replication.
OPV and other live virus
vaccines (such as MMR)
should be administered at
least 1 month apart.

Availability

Route of
Administration
Oral

Pregnancy Risk
Category
OPV is classified as pregnancy
category C. Poliovirus
antibodies may be excreted into
breast milk, and breast-feeding
is not recommended for 2-3
hours before or after inoculation
in neonates immunized at birth.

Adverse Reaction

General Indications

OPV may not be as

immunogenic in elderly patients
or in patients suffering from
immunosuppression (congenital,
acquired, or iatrogenic).
Patients with HIV infection may
receive IPV however, OPV
should be avoided. Patients
with evidence of viral infection
(diarrhea, vomiting) should not
be given OPV. IM injections,
especially antibiotics, should be
avoided for at least 30 days in
OPV recipients or for 60 days in
patients who acquired the
disease by contact with vaccine
recipients

live attenuated poliovirus

(Sabin strain types 1, 2
and 3)

Height: __________
Weight: __________
Body Build: _________

Patients Actual
Indications

Nursing
Responsibility
Before

During

After

Name of Patient: _____________________________

Diagnosis: __________________________________
Physician: __________________________________

Age: _____
Sex: _____
Date of Admission: _______________

Height: __________
Weight: __________
Body Build: _________

Source:

Source:

Source:

Source:

Source:

Source:

Source:

http://www.rxlist.com/ori
mune-drug.htm

http://www.rxlist.com/ori
mune-drug.htm

http://www.rxlist.com/ori
mune-drug.htm

http://www.rxlist.com/ori
mune-drug.htm

http://www.rxlist.com/ori
mune-drug.htm

http://www.rxlist.com/ori
mune-drug.htm

http://www.rxlist.com/orimun
e-drug.htm